Instrument Inactif

Communiqués Keryx Biopharmaceuticals

Actions

US4925151015

Communiqués

11/12/18	Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics	GL
29/11/18	Keryx Biopharmaceuticals : ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics	PU
29/11/18	ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics	GL
15/11/18	Keryx Biopharmaceuticals : Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company	BU
08/11/18	Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results	GL
06/11/18	Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018	GL
02/10/18	Rigrodsky & Long, P.A. Announces Investigation of Keryx Biopharmaceuticals, Inc. Merger	BU
01/10/18	Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference	GL
08/08/18	Keryx Biopharmaceuticals : Announces Second Quarter 2018 Financial Results	PU
08/08/18	Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results	GL
02/08/18	Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018	GL
05/07/18	KERYX BIOPHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Merger	BU
28/06/18	Keryx Biopharmaceuticals : Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease	BU
20/06/18	Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st	GL
30/05/18	Keryx Pharmaceuticals Announces Upcoming Investor Presentations	GL
25/05/18	Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen	GL
10/05/18	Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results	GL
30/04/18	Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue	GL
19/04/18	Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress	GL
11/04/18	Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation	GL
04/04/18	Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology	GL
07/02/18	Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results	GL
02/02/18	Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018	GL
22/12/17	Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 36th Annual Healthcare Conference on January 10, 2018	GL
08/11/17	Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017	GL